Rockville, Maryland – Rise Therapeutics, a biotechnology company engaged in developing novel oral immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a rheumatoid arthritis Phase 1 clinical trial for its program candidate, R-2487. This is Rise Therapeutics’ second clinical program developed using synthetic biology and its proprietary oral biologics delivery platform.

TEDCO, Maryland’s economic engine for technology companies, announced a recent Seed Funds investment of $200,000 into Rise Therapeutics, a Maryland-based biotechnology company. TEDCO’s Seed Funds invest in early-stage, technology and life sciences companies and provides access to gap financing.

Rockville, Maryland - Rise Therapeutics, a biotech company focused on developing novel immunological-directed synthetic biology-based therapeutics, announced today that it has received funding from the National Institutes of Health (NIH) to develop a novel therapeutic for Acute Respiratory Distress Syndrome (ARDS). The funding will support completion of product validation studies and preparation for clinical development for the program.

Rockville, Maryland, January 31^st, 2023 – Rise Therapeutics, a biopharmaceutical company engaged in developing novel oral synthetic biology medicines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a Phase 1 clinical trial of its lead program candidate, R-3750.

Lebanon, NH: The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has awarded Celdara Medical, LLC a Phase I Small Business Innovation Research (SBIR) grant for development of broad-spectrum antimicrobial peptides to combat chronic lung infection in patients with cystic fibrosis (CF).

Seattle, Washington - Virtici LLC announced today that the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH) has awarded a Small Business Innovation Research (SBIR) award to advance VTC-886, a first-in-class small molecule for the prevention of P. gingivalis infection.